Straits Times Index
3,292.69 +10.64 (+0.32%) Nikkei
38,150.08 -123.97 (-0.32%) Hang Seng
17,763.03 +16.12 (+0.09%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,779.15 -2,329.42 (-3.88%) CMC Crypto 200
1,266.82 -72.25 (-5.39%)
GSK plc (GLAXF)
| Previous close | 20.80 |
| Open | 20.04 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 20.04 - 21.00 |
| 52-week range | 16.65 - 22.14 |
| Volume | |
| Avg. volume | 1,308 |
| Market cap | 86.174B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 14.00 |
| EPS (TTM) | 1.50 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | 0.80 (3.86%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
BenzingaGSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Wednesday, GSK Plc (NYSE:GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% excluding COVID. Vaccines’ sales increased 16% at constant currency to 2.28 billion Pounds, reflecting U.S. demand for Arexvy and strong market growth for Shingrix in International and European markets. Shingrix sales reached 945 million Pounds, up 18% at constant currency, with Arexvy sales of 182 million Pounds. Specialty Medicine sales increased 17% to 2.5 billion poun
PA Media: MoneyGSK raises profit guidance as vaccine demand grows
Emma Walmsley, chief executive officer of the pharmaceutical firm hailed a ‘strong start to 2024’.
ZacksGSK (GSK) Q1 Earnings and Revenues Surpass Estimates
Glaxo (GSK) delivered earnings and revenue surprises of 15.96% and 3.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
